Firstly, the MSB and the Osiris cells are different and distinct (they had to be, otherwise MSB would never have got their patent - when you read both patents, you will see how MSB clearly differentiates their cells from the Osiris cells, two totally different cell populations). So the MOA might be subtly or even quite different - and in any case would need to be separately identified and established.
Secondly, the manufacturing process is totally different - the Osiris process is based on adhesion to plastic, the MSB process on antibody binding. So the CMC package will be majorly different.
On the plus side, MSB will benefit from their experience with the Osiris cells - despite my comments above there will be some commonalities such as basic GMP procedures related to cell processing. They will also be able to leverage their MOA experience with the Osiris cells to help them build the necessary case for their own cells.
Easier? Yes. Plain sailing? No!
MSB Price at posting:
86.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)